【佳學(xué)基因檢測(cè)】基因表達(dá)分析確定了 1 型神經(jīng)纖維瘤病的潛在生物標(biāo)志物,包括腎上腺髓質(zhì)素
靶向藥一般多少錢排名
研究高效抑制腫瘤轉(zhuǎn)移的方法與藥物看到《Clin Cancer Res》在.?2010 Oct 15;16(20):5048-57.發(fā)表了一篇題目為《基因表達(dá)分析確定了 1 型神經(jīng)纖維瘤病的潛在生物標(biāo)志物,包括腎上腺髓質(zhì)素》腫瘤靶向藥物治療基因檢測(cè)臨床研究文章。該研究由Trent R Hummel?,?Walter J Jessen,?Shyra J Miller,?Lan Kluwe,?Victor F Mautner,?Margaret R Wallace,?Conxi Lázaro,?Grier P Page,?Paul F Worley,?Bruce J Aronow,?Elizabeth K Schorry,?Nancy Ratner等完成。促進(jìn)了腫瘤的正確治療與個(gè)性化用藥的發(fā)展,進(jìn)一步強(qiáng)調(diào)了基因信息檢測(cè)與分析的重要性。
腫瘤全國(guó)篩查臨床研究?jī)?nèi)容關(guān)鍵詞:
基因表達(dá)分析確,1 型神經(jīng)維瘤,標(biāo)志物,包,轉(zhuǎn)移
腫瘤靶向治療基因檢測(cè)臨床應(yīng)用結(jié)果
目的:叢狀神經(jīng)纖維瘤 (pNF) 是在三分之一的 1 型神經(jīng)纖維瘤病 (NF1) 患者中發(fā)現(xiàn)的雪旺氏細(xì)胞腫瘤。 pNF 可以轉(zhuǎn)化為惡性周圍神經(jīng)鞘瘤 (MPNST)。沒有確定的 pNF 腫瘤負(fù)荷或轉(zhuǎn)化為 MPNST 的血清生物標(biāo)志物。血清生物標(biāo)志物可用于驗(yàn)證 NF1 診斷、監(jiān)測(cè)腫瘤負(fù)荷和/或檢測(cè)轉(zhuǎn)化。實(shí)驗(yàn)設(shè)計(jì):我們使用微陣列基因表達(dá)分析來(lái)定義編碼神經(jīng)纖維瘤雪旺細(xì)胞、神經(jīng)纖維瘤和 MPNST 中推定的分泌蛋白的 92 個(gè)基因。我們通過(guò)定量逆轉(zhuǎn)錄-PCR、蛋白質(zhì)印跡和 ELISA 測(cè)定在細(xì)胞條件培養(yǎng)基和對(duì)照以及 NF1 患者血清中驗(yàn)證了差異表達(dá)。結(jié)果:在評(píng)估的 13 個(gè)候選基因中,只有腎上腺髓質(zhì)素 (ADM) 被證實(shí)在血清中差異表達(dá)和升高NF1 患者。一小部分患有 MPNST 的 NF1 患者的血清中 ADM 蛋白濃度進(jìn)一步升高。含有 ADM 和肝細(xì)胞生長(zhǎng)因子的 MPNST 細(xì)胞條件培養(yǎng)基可刺激 MPNST 遷移和內(nèi)皮細(xì)胞增殖。結(jié)論:因此,微陣列分析確定了疾病的潛在血清生物標(biāo)志物,而 ADM 是 NF1 的血清生物標(biāo)志物。 ADM 血清水平似乎與 pNF 的存在無(wú)關(guān),但可能是轉(zhuǎn)化為 MPNST 的生物標(biāo)志物。
腫瘤發(fā)生與反復(fù)轉(zhuǎn)移國(guó)際數(shù)據(jù)庫(kù)描述:
Purpose:?Plexiform neurofibromas (pNF) are Schwann cell tumors found in a third of individuals with neurofibromatosis type 1 (NF1). pNF can undergo transformation to malignant peripheral nerve sheath tumors (MPNST). There are no identified serum biomarkers of pNF tumor burden or transformation to MPNST. Serum biomarkers would be useful to verify NF1 diagnosis, monitor tumor burden, and/or detect transformation.Experimental design:?We used microarray gene expression analysis to define 92 genes that encode putative secreted proteins in neurofibroma Schwann cells, neurofibromas, and MPNST. We validated differential expression by quantitative reverse transcription-PCR, Western blotting, and ELISA assays in cell conditioned medium and control and NF1 patient sera.Results:?Of 13 candidate genes evaluated, only adrenomedullin (ADM) was confirmed as differentially expressed and elevated in serum of NF1 patients. ADM protein concentrati on was further elevated in serum of a small sampling of NF1 patients with MPNST. MPNST cell conditioned medium, containing ADM and hepatocyte growth factor, stimulated MPNST migration and endothelial cell proliferation.Conclusions:?Thus, microarray analysis identifies potential serum biomarkers for disease, and ADM is a serum biomarker of NF1. ADM serum levels do not seem to correlate with the presence of pNFs but may be a biomarker of transformation to MPNST.
(責(zé)任編輯:佳學(xué)基因)